Please ensure Javascript is enabled for purposes of website accessibility

Better Coronavirus Stock: Moderna or Inovio Pharmaceuticals?

By Adria Cimino – May 31, 2020 at 12:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus vaccine race offers these clinical stage companies an opportunity to bring a first product to market -- if all goes well in human trials.

From a timeline perspective, Moderna (MRNA 3.87%) and Inovio Pharmaceuticals (INO 6.39%) are close rivals in the race to develop a vaccine for COVID-19. Moderna was the first to start human trials in March, and Inovio began its human trial less than a month later.

Both stocks have skyrocketed since the start of the year. Moderna has soared 182%, while Inovio has jumped 304% as investors bet on their coronavirus vaccine programs.

Vials of vaccine are positioned on a glass table.

Image source: Getty Images.

But which of the two is the best coronavirus stock to buy? Let's take a closer look.

The pipelines

Moderna and Inovio are both clinical stage biotech companies, meaning they haven't yet brought a product to market. Besides the COVID-19 vaccine, Moderna's most advanced product is in phase 2 testing. The company has more than 20 candidates in the pipeline for indications including influenza, Zika, and various types of cancer.

Moderna's technology involves harnessing the power of messenger RNA (mRNA). The investigational products use messenger RNA to give the body's cells instructions to make proteins that would prevent or treat disease.

Inovio has about 15 candidates in the pipeline, most of which are in phase 2 testing. The company develops medicines for infectious diseases and cancer. Inovio's lead candidate is currently in phase 3 trials for precancerous cervical dysplasia, and the company plans on reporting top-line efficacy data in the fourth quarter.

Inovio's treatments involve the use of optimized DNA plasmids. Through computer sequencing, these small circles of double stranded DNA are reorganized to produce a specific immune response in the body. Inovio then delivers these plasmids intradermally or intramuscularly through the company's own handheld smart device.

The coronavirus programs

As the U.S. government has vowed to help accelerate the development of a coronavirus vaccine, Moderna and Inovio have an opportunity to bring a product to market sooner than they would have in pre-coronavirus times. That is, if all goes well in clinical trials.

So far, Moderna is a step ahead in terms of timeline and funding. The company recently reported interim data from its phase 1 trial involving 45 healthy volunteers. Results on neutralizing antibodies, or those that stop infection, were only available for a total of eight people. In those participants, neutralizing antibodies were at or above levels of those of recovered coronavirus patients.

That is promising, but before getting too excited, we should wait to see if the trend is the same across all participants. The U.S. Food and Drug Administration gave Moderna the nod to start a phase 2 trial involving 600 participants, and a phase 3 trial is expected to start in July.

As for funding, the U.S. Department of Health and Human Services (HHS) recently granted Moderna as much as $483 million. That's enough to carry the vaccine through regulatory approval and support a scale-up in manufacturing, Moderna said.

Inovio's phase 1 study in 40 healthy volunteers is set to report preliminary data on safety and immune response in late June. The company said preclinical studies have shown "robust" neutralizing antibody and T cell immune responses. Inovio plans on beginning a phase 2/3 efficacy study in July or August if all goes well in the earlier trial.

Inovio's biggest award comes from the Coalition for Epidemic Preparedness Innovations. The global organization to accelerate vaccine development has awarded Inovio more than $17 million for its COVID-19 program.

Which stock to choose?

Moderna's and Inovio's pipelines are based on mRNA and DNA technology, respectively. That means victory in the coronavirus program not only opens the door to commercialization of a product, but also offers evidence of those technologies' efficacy in humans. That could be a big step forward for both companies.

At this stage, it's impossible to say which company will win this race to find a vaccine -- or even make it to the finish line. During clinical trials, anything can happen at any point. And share gains have been significant, pushing Moderna and Inovio prices above Wall Street's average estimates by 47% and 6%, respectively. For these two reasons, investment in Moderna and Inovio should be done with extreme caution.

That said, if I had to choose between the two biotech stocks, I would favor Moderna because it offers a bit more visibility. The company has started to deliver some human data, and so far, the results have been encouraging. And the amount of government funding is another plus, meaning Moderna may not stumble financially to bring this potential product to market.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.83 (6.39%) $0.11
Moderna, Inc. Stock Quote
Moderna, Inc.
$125.67 (3.87%) $4.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.